Public Patent Foundation
Pfizer Lipitor Patent » PUBPAT Receives Substantial Victory in Lipitor Patent Challenge

PUBPAT RECEIVES SUBSTANTIAL VICTORY IN LIPITOR PATENT CHALLENGE: Pfizer Concedes to Give Up Original Broad Patent Claims

NEW YORK -- November 29, 2005 -- The Public Patent Foundation ("PUBPAT") said today that in the challenge it filed last year against Pfizer Inc.'s (NYSE: PFE) patent on Lipitor, touted by the pharmaceutical giant as being "the best-selling treatment for lowering cholesterol and the best-selling pharmaceutical product of any kind in the world," Pfizer has conceded to significantly narrow the patent to specifically exclude the form of atorvastatin tested in its early clinical trials for Lipitor.
 
"This is a substantial victory for the public," said Dan Ravicher, PUBPAT's Executive Director.  "Pfizer has been caught with its hand in the cookie jar and is correctly giving up the undeserved breadth of the patent it was originally issued."
 
More information about the reexamination of Pfizer's Lipitor patent can be found at PUBPAT > Pfizer Lipitor Patent.
###

© 2003 - 2015 Public Patent Foundation | Contact | RSS